Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 103Recruiting 30Active not recruiting 28Terminated 23Unknown 16Withdrawn 5Not yet recruiting 5Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 40Head & Neck 28Gastrointestinal 27Gynecologic 12Genitourinary 5Other solid neoplasm 4Breast 4Tumor-Agnostic 1NET 1Lymphoid 1Endocrine 1Dermatologic 1CNS 1

Conditions

Urinary Bladder Neoplasms 5Neoplasms 1

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 8toripalimab 7darolutamide 7Drug Therapy 7Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Axitinib 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Cyclophosphamide 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Cisplatin × Genitourinary × Clear all
NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

University of Washington

Phase 1/2 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

University of Washington

Phase 2 Not yet recruiting
33 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07184021 2025-09-19

No Acronym

Assiut University

Phase 2 Not yet recruiting
30 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
210 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡